Minerva Neurosciences(US:NERV)2026-03-11 11:07Clinical Trials - Minerva Neurosciences plans to initiate a confirmatory Phase 3 trial with roluperidone for negative symptoms of schizophrenia in Q2 2026, with topline data expected in 2H 2027[1]. - The company plans to focus on the successful execution of the Phase 3 trial for roluperidone, which could potentially shift the treatment paradigm for negative symptoms of schizophrenia[26]. Financial Performance - The net loss for Q4 2025 was $283.7 million, or $25.51 per share, compared to a net loss of $4.3 million, or $0.56 per share, in Q4 2024[17]. - For the year ended December 31, 2025, the net loss was $293.4 million, or $34.67 per share, compared to a net income of $1.4 million, or $0.19 per share, in 2024[18]. - Non-GAAP adjusted net loss for Q4 2025 was $7.1 million, or $0.64 per share, compared to a non-GAAP adjusted net loss of $4.0 million, or $0.53 per share, in Q4 2024[17]. - The net loss for the three months ended December 31, 2025, was $283,668,000 compared to a loss of $4,272,000 for the same period in 2024[29]. - Adjusted net loss income for the three months ended December 31, 2025, was $7,100,000, compared to a loss of $4,022,000 in 2024[31]. Expenses - Research and development (R&D) expenses for Q4 2025 were $2.2 million, up from $2.0 million in Q4 2024, while total R&D expenses for the year were $5.8 million, down from $11.9 million in 2024[8]. - General and administrative (G&A) expenses for Q4 2025 were $2.8 million, compared to $2.5 million in Q4 2024, with total G&A expenses for the year decreasing to $9.3 million from $9.9 million in 2024[9]. - Research and development expenses for the twelve months ended December 31, 2025, were $5,759,000, down from $11,899,000 in 2024, indicating a reduction of 52%[29]. Cash and Assets - Cash, cash equivalents, and restricted cash at December 31, 2025, were approximately $82.4 million, up from $21.5 million at December 31, 2024[19]. - Total current assets increased to $83,100,000 in December 2025 from $22,269,000 in December 2024, representing a growth of 273%[28]. - Total assets rose to $97,969,000 in December 2025, up from $37,144,000 in December 2024, marking a 164% increase[28]. Liabilities - Total liabilities as of December 31, 2025, were $233.8 million, significantly higher than $62.8 million in 2024[16]. - Total liabilities increased significantly to $233,755,000 in December 2025 from $62,837,000 in December 2024, reflecting a growth of 272%[30]. - The warrant liability was recorded at $171,465,000 as of December 31, 2025, indicating a new financial obligation[30]. - The accumulated deficit increased to $688,799,000 in December 2025 from $395,377,000 in December 2024, reflecting a rise of 74%[28]. Funding - The company received $80.0 million in gross proceeds from a private placement on October 23, 2025, with potential additional proceeds of up to $120.0 million if all warrants are exercised[3]. - The company recorded a loss of $321.5 million on the issuance of convertible preferred stock and warrants in 2025, reflecting the fair values of the issued securities[13].